Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 4, 2017, Pages E448-E456

  McKinlay, Colin J ^a   Vargas, Jessica R ^a   Blake, Timothy R ^a   Hardy, Jonathan W ^a   Kanada, Masamitsu ^a   Contag, Christopher H ^a,b   Wender, Paul A ^a   Waymouth, Robert M ^a  

^a STANFORD UNIVERSITY   (United States)

^b Stanford University   (United States)

Author keywords

Cell penetrating; Gene therapy; Nanoparticle; Organocatalysis; Stimuli responsive

Indexed keywords

CHARGE ALTERING RELEASABLE TRANSPORTER; DRUG CARRIER; MESSENGER RNA; UNCLASSIFIED DRUG; BIOMATERIAL; CARBOCYANINE; CYANINE DYE 5; ENHANCED GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; CELL CULTURE; CONFERENCE PAPER; CONTROLLED STUDY; EMBRYO; FEMALE; GENE DELIVERY SYSTEM; GENE EXPRESSION; HEK293 CELL LINE; HELA CELL LINE; HEP-G2 CELL LINE; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA TRANSLATION; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; GENE TRANSFER; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; TUMOR CELL LINE;

ANIMALS; BIOCOMPATIBLE MATERIALS; CARBOCYANINES; CELL LINE; CELL LINE, TUMOR; CELLS, CULTURED; FEMALE; GENE TRANSFER TECHNIQUES; GREEN FLUORESCENT PROTEINS; HUMANS; MESENCHYMAL STROMAL CELLS; MICE, INBRED BALB C; RNA, MESSENGER;

EID: 85011003733     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1614193114     Document Type: Article

References (61)

1. Sahin U, Karikó K, Türeci Ö (2014) mRNA-based therapeutics-Developing a new class of drugs. Nat Rev Drug Discov 13(10):759-780.
2. McIvor RS (2011) Therapeutic delivery of mRNA: The medium is the message. Mol Ther 19(5):822-823.
3. Kranz LM, et al. (2016) Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534(7607):396-401.
4. Chahal JS, et al. (2016) Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc Natl Acad Sci USA 113(29):E4133-E4142.
5. Yin H, et al. (2016) Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat Biotechnol 34(3):328-333.
6. Vallazza B, et al. (2015) Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond. Wiley Interdiscip Rev RNA 6(5):471-499.
7. Kreiter S, Diken M, Sahin U (2014) mRNA vaccination and personalized cancer therapy. Cancer Immunotherapy Meets Oncology, eds Britten CM, Kreiter S, Diken M, Rammensee H-G (Springer, Berlin), pp 89-100.
8. Whitehead KA, Langer R, Anderson DG (2009) Knocking down barriers: Advances in siRNA delivery. Nat Rev Drug Discov 8(2):129-138.
9. Pack DW, Hoffman AS, Pun S, Stayton PS (2005) Design and development of polymers for gene delivery. Nat Rev Drug Discov 4(7):581-593.
10. Putnam D (2006) Polymers for gene delivery across length scales. Nat Mater 5(6):439-451.
11. Tezgel AÖ, et al. (2013) Novel protein transduction domain mimics as nonviral delivery vectors for siRNA targeting NOTCH1 in primary human T cells. Mol Ther 21(1): 201-209.
12. Lee JB, Hong J, Bonner DK, Poon Z, Hammond PT (2012) Self-assembled RNA interference microsponges for efficient siRNA delivery. Nat Mater 11(4):316-322.
13. Luo D, Saltzman WM (2000) Synthetic DNA delivery systems. Nat Biotechnol 18(1): 33-37.
14. Kauffman KJ, Webber MJ, Anderson DG (2016) Materials for non-viral intracellular delivery of messenger RNA therapeutics. J Control Release 240:227-234.
15. Yin H, et al. (2014) Non-viral vectors for gene-based therapy. Nat Rev Genet 15(8): 541-555.
16. Tavernier G, et al. (2011) mRNA as gene therapeutic: How to control protein expression. J Control Release 150(3):238-247.
17. Sharova LV, et al. (2009) Database for mRNA half-life of 19 977 genes obtained by DNA microarray analysis of pluripotent and differentiating mouse embryonic stem cells. DNA Res 16(1):45-58.
18. Islam MA, et al. (2015) Biomaterials for mRNA delivery. Biomater Sci 3(12):1519-1533.
19. Bettinger T, Carlisle RC, Read ML, Ogris M, Seymour LW (2001) Peptide-mediated RNA delivery: A novel approach for enhanced transfection of primary and post-mitotic cells. Nucleic Acids Res 29(18):3882-3891.
20. Schlake T, Thess A, Fotin-Mleczek M, Kallen K-J (2012) Developing mRNA-vaccine technologies. RNA Biol 9(11):1319-1330.
21. Habrant D, et al. (2016) Design of ionizable lipids to overcome the limiting step of endosomal escape: Application in the intracellular delivery of mRNA, DNA, and siRNA. J Med Chem 59(7):3046-3062.
22. Rejman J, Tavernier G, Bavarsad N, Demeester J, De Smedt SC (2010) mRNA transfection of cervical carcinoma and mesenchymal stem cells mediated by cationic carriers. J Control Release 147(3):385-391.
23. Gonçalves C, Akhter S, Pichon C, Midoux P (2016) Intracellular availability of pDNA and mRNA after transfection: A comparative study among polyplexes, lipoplexes, and lipopolyplexes. Mol Pharm 13(9):3153-3163.
24. Kübler H, et al. (2015) Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: A first-in-man phase I/IIa study. J Immunother Cancer 3(1):26.
25. Weide B, et al. (2009) Direct injection of protamine-protected mRNA: Results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother 32(5): 498-507.
26. Rittig SM, et al. (2011) Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther 19(5):990-999.
27. Cheng C, Convertine AJ, Stayton PS, Bryers JD (2012) Multifunctional triblock copolymers for intracellular messenger RNA delivery. Biomaterials 33(28):6868-6876.
28. Uzgün S, et al. (2011) PEGylation improves nanoparticle formation and transfection efficiency of messenger RNA. Pharm Res 28(9):2223-2232.
29. Nuhn L, Kaps L, Diken M, Schuppan D, Zentel R (2016) Reductive decationizable block copolymers for stimuli-responsive mRNA delivery. Macromol Rapid Commun 37(11): 924-933.
30. Uchida S, et al. (2013) In vivo messenger RNA introduction into the central nervous system using polyplex nanomicelle. PLoS One 8(2):e56220.
31. Uchida H, et al. (2014) Modulated protonation of side chain aminoethylene repeats in N-substituted polyaspartamides promotes mRNA transfection. J Am Chem Soc 136(35):12396-12405.
32. Crowley ST, Poliskey JA, Baumhover NJ, Rice KG (2015) Efficient expression of stabilized mRNA PEG-peptide polyplexes in liver. Gene Ther 22(12):993-999.
33. Fenton OS, et al. (2016) Bioinspired alkenyl amino alcohol ionizable lipid materials for highly potent in vivo mRNA delivery. Adv Mater 28(15):2939-2943.
34. Li B, et al. (2015) An orthogonal array optimization of lipid-like nanoparticles for mRNA delivery in vivo. Nano Lett 15(12):8099-8107.
35. Kauffman KJ, et al. (2015) Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs. Nano Lett 15(11):7300-7306.
36. Brito LA, et al. (2014) A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Ther 22(12):2118-2129.
37. Matsui A, Uchida S, Ishii T, Itaka K, Kataoka K (2015) Messenger RNA-based therapeutics for the treatment of apoptosis-associated diseases. Sci Rep 5:15810.
38. Dove AP, Pratt RC, Lohmeijer BGG, Waymouth RM, Hedrick JL (2005) Thiourea-based bifunctional organocatalysis: Supramolecular recognition for living polymerization. J Am Chem Soc 127(40):13798-13799.
39. Pratt RC, et al. (2006) Exploration, optimization, and application of supramolecular thiourea-amine catalysts for the synthesis of lactide (co)polymers. Macromolecules 39(23):7863-7871.
40. Kamber NE, et al. (2007) Organocatalytic ring-opening polymerization. Chem Rev 107(12):5813-5840.
41. Blake TR, Waymouth RM (2014) Organocatalytic ring-opening polymerization of morpholinones: New strategies to functionalized polyesters. J Am Chem Soc 136(26): 9252-9255.
42. Lynn DM, Langer R (2000) Degradable poly(β-amino esters): Synthesis, characterization, and self-assembly with plasmid DNA. J Am Chem Soc 122(44):10761-10768.
43. Green J, Zugates G, Langer R, Anderson D (2009) Poly(beta-amino esters): Procedures for synthesis and gene delivery. Methods Mol Biol 480:53-63.
44. Requena JR, et al. (1997) Carboxymethylethanolamine, a biomarker of phospholipid modification during the maillard reaction in vivo. J Biol Chem 272(28):17473-17479.
45. Pratt RC, Nederberg F, Waymouth RM, Hedrick JL (2008) Tagging alcohols with cyclic carbonate: A versatile equivalent of (meth)acrylate for ring-opening polymerization. Chem Commun (Camb) (1):114-116.
46. Geihe EI, et al. (2012) Designed guanidinium-rich amphipathic oligocarbonate molecular transporters complex, deliver and release siRNA in cells. Proc Natl Acad Sci USA 109(33):13171-13176.
47. Wender PA, Huttner MA, Staveness D, Vargas JR, Xu AF (2015) Guanidinium-rich, glycerol-derived oligocarbonates: A new class of cell-penetrating molecular transporters that complex, deliver, and release siRNA. Mol Pharm 12(3):742-750.
48. deRonde BM, et al. (2016) Optimal hydrophobicity in ring-opening metathesis polymerization-based protein mimics required for siRNA internalization. Biomacromolecules 17(6):1969-1977.
49. Cooley CB, et al. (2009) Oligocarbonate molecular transporters: Oligomerizationbased syntheses and cell-penetrating studies. J Am Chem Soc 131(45):16401-16403.
50. Huss M, et al. (2002) Concanamycin A, the specific inhibitor of V-ATPases, binds to the V(o) subunit c. J Biol Chem 277(43):40544-40548.
51. Khalil IA, Kogure K, Akita H, Harashima H (2006) Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev 58(1):32-45.
52. Bartz R, et al. (2011) Effective siRNA delivery and target mRNA degradation using an amphipathic peptide to facilitate pH-dependent endosomal escape. Biochem J 435(2): 475-487.
53. Akinc A, Thomas M, Klibanov AM, Langer R (2005) Exploring polyethyleniminemediated DNA transfection and the proton sponge hypothesis. J Gene Med 7(5): 657-663.
54. Kichler A, Leborgne C, Coeytaux E, Danos O (2001) Polyethylenimine-mediated gene delivery: A mechanistic study. J Gene Med 3(2):135-144.
55. Erbacher P, Roche AC, Monsigny M, Midoux P (1996) Putative role of chloroquine in gene transfer into a human hepatoma cell line by DNA/lactosylated polylysine complexes. Exp Cell Res 225(1):186-194.
56. Zhang X, Edwards JP, Mosser DM (2009) The expression of exogenous genes in macrophages: Obstacles and opportunities. Methods Mol Biol 531:123-143.
57. Contag CH, Bachmann MH (2002) Advances in in vivo bioluminescence imaging of gene expression. Annu Rev Biomed Eng 4(1):235-260.
58. Nguyen TH, Ferry N (2004) Liver gene therapy: Advances and hurdles. Gene Ther 11(Suppl 1):S76-S84.
59. Nguyen TH, Ferry N (2007) Gene therapy for liver enzyme deficiencies: What have we learned from models for Crigler-Najjar and tyrosinemia? Expert Rev Gastroenterol Hepatol 1(1):155-171.
60. Suda T, et al. (2009) Progress toward liver-based gene therapy. Hepatol Res 39(4): 325-340.
61. Huang S, et al. (2015) An improved protocol for isolation and culture of mesenchymal stem cells from mouse bone marrow. J Orthopaedic Trans 3(1):26-33.